The Accuracy of Liver Biopsy to Diagnose Biliary Atresia: A Meta-Analysis

Yuan Yang1, Xin Li2 and Jianghua Zhan*

1Department of Pediatric Surgery, Tianjin Children’s Hospital, Tianjin, 300074, China
2Department of General Pediatric Surgery, Urumqi First People’s Hospital (Urumqi Children’s Hospital), Xinjiang Uygur Autonomous Region, 830002, China

Abstract

Objectives: A lot of prolonged jaundice patients may undergo many tests before confirmed diagnosis. Liver biopsy is an effective way in final stage of the course. This article aims to evaluate the accuracy of liver biopsy to diagnose biliary atresia (BA) in infants with cholestasis.

Methods: We searched PubMed, EMBASE and the Web of Science databases for articles evacuated the accuracy of liver biopsy to diagnose BA to obtain the sensitivity, specificity, TN, FN, FP, TP. The methodological quality of liver biopsy was assessed with version 2 of the Quality Assessment of Diagnostic Accuracy Studies tool. Screening, data extraction, and quality assessment were done in duplicated.

Results: A total of 20 articles were included. The whole data results the Diagnostic Odds Ratio of liver biopsy was 170.39 (94.90 to 341.97), with a pooled sensitivity of 92% (90%-94%), pooled specificity of 95% (93%-95%).

Conclusion: Quantitative analysis demonstrated liver biopsy to be high sensitivity, high specificity, high accuracy in diagnosing BA. The data analysis provides evidence of liver biopsy is a reliable diagnosis method to confirm diagnosis.

Introduction

Biliary atresia (BA) is a disease with unknown etiology that affects both the extrahepatic and intrahepatic bile ducts, it is a progressive, obliterate fibro-inflammatory disease in infancy [1]. BA is most common reason of causing pathologic jaundice in infants, accounting for more than 30% neonates have obstructive cholestasis, cirrhosis and end-stage liver disease in first year of life. And it is the most common indication for liver transplantation in infants [2]. Many investigators aim to solve the dilemma of early diagnosis of BA, it is particularly distinguished it from other causes of neonatal cholestasis (NC) without need of cholangiography [3]. So it is very important to make differential diagnosis of BA and other neonatal cholestasis as soon as possible. Liver biopsy is seemed as the second gold standard of diagnosing BA, but it has many demerits. Therefore, the purpose of our study is to evaluate liver biopsy to diagnose BA in infants with cholestasis.

Methods

Literature search

We searched PubMed, EMBASE and the Web of Science databases for articles published all up to December 2017, using following terms (BA [Title/Abstract]) AND (liver biopsy [Title/Abstract]), (cholestasis [Title/Abstract]) AND (liver biopsy [Title/Abstract]), (infantile jaundice [Title/Abstract]) AND (liver biopsy [Title/Abstract]) without any language or data limits. Reference lists of the relevant studies were evaluated for any possible missed citation. Cited articles of each relevant study were also reviewed for any other possible relevant study.

Inclusion criteria

The inclusion criteria for identified articles were as follows:

What is known?

1. Liver biopsy is a useful way to diagnose biliary atresia.
2. Liver biopsy is an invasive way compared to B-ultrasound scanner, MRCP, ERCP and so on.

What is new?

1. Liver biopsy can make differential diagnosis to other cholestasis.
2. Liver biopsy has many advantages and shortcomings.

1. Use pre-operative liver biopsy or percutaneous liver biopsy or ultrasonic guided liver biopsy. All measure about liver biopsy was finished before surgery.
2. Data including: at least one of the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy or have definite number of TN (True Negative), FN (False Negative), FP (False Positive), TP (True Positive).
3. Articles were published in full texts in English.
4. Studies with other sufficient information for analysis.
5. The confirmed diagnosis of BA used cholangiography as golden standard

Exclusion criteria

The exclusion criteria for the identified articles were as follows:

1. Letters, reviews, case reports, and conference abstracts, editorials, and expert opinion reviews and abstracts.
2. Data deficiency to analysis or false data.
3. Studies with overlapping cases and data. If cases of two or more studies overlap each other, give priority to the study with

*Corresponding Author: Dr. Jianghua Zhan, Department of Pediatric Surgery, Tianjin Children’s Hospital, Longyan Road 238, Beichen District, Tianjin, 300134, China; E-mail: zhanjianghua@163.com

Citation: Yang Y, Li X, Zhan J (2020) The Accuracy of Liver Biopsy to Diagnose Biliary Atresia: A Meta-Analysis. Int J Clin Res Trials 5: 144. doi: https://doi.org/10.15344/2456-8007/2020/144

Copyright: © 2020 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
more diagnosis methods evaluated and whose cases are more if diagnosis methods are the same.

4. Use intraoperative liver biopsy or intraoperative frozen section to diagnose BA.

Screening

Retrieved articles were evaluated blindly by two of authors and in case of any disagreement the opinion of a third author was used.

Data extraction

Data were extracted on study characteristics. Extract the data of the commonest criteria if the study evaluates two or more criteria of a diagnosis method.

Quality assessment

Using the version 2 of the Quality Assessment of Diagnostic Test Accuracy Studies (QUADAS-2) tool [4], quality of studies included in our study was assessed by two researchers.

Data analysis

For those studies where the TP, FP, FN, and FN were available, forest plots were generated for the sensitivity and specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), diagnostic odds ratio (DOR) with 95% CIs, PPV and NPV using Meta-Disc. Pooled averages of sensitivity, specificity, and accuracy are calculated as the sum of individual data weighed based on sample size. We constructed a summary receiver operator characteristic curve (SROC) and calculated the area under curve (AUC). Heterogeneity was assessed using the I2 statistic index. When a great heterogeneity was noted, heterogeneity by a “threshold effect” was analyzed using Spearman correlation coefficients (p<0.05 represents threshold effect). We evaluated the effects of age, wound degree and serum bilirubin level on the accuracy of liver biopsy by using chi-square and independent sample t-tests and the binary logistic regression method. We also made subgroup analyses on study design (prospective versus retrospective), cases (<60 versus ≥60) to discuss the heterogeneity. SPSS software version 11.5 was used for these statistical analyses (SPSS, Chicago, IL). And publication bias is assessed by a Deeks funnel plot (p 0.05 was considered representative of significant statistical publication bias). And publication bias was analyzed by StataMP-64.

Result

Study selection

Data extracted from the 20 included studies had information regarding 1582 patients for further assessment. Figure 1 shows the flow of studies through the review (20 studies were listed in reference [5-24]). Initial search of PubMed, EMBASE and the Web of Science provide 3303 studies. After de-duplication, a total of 2090 studies remained for screening. Following title and abstract screening, 236 studies were included, to read the full text leaving 53 full text articles to be assessed for final eligibility. Of the 53 full text articles assessed a further screening, 20 studies met the appropriate inclusion and exclusion criteria. 33 studies were excluded (5 full text could not be obtained, 1 non-English, 15 insufficient data to construct diagnostic 2-by-2 table, 1 evaluated by two or more researcher without a consensus, 9 with incorrect data, 2 with overlapping patients). All the included articles compare liver biopsy with cholangiography as the golden standard.

Figure 1: Flow diagram of the study selection process.
| Study              | Year | Location | Sample | Study design | Gender (female: male) | MINORS Score |
|--------------------|------|----------|--------|--------------|----------------------|--------------|
| Yang et.al         | 2009 | China    | 69     | R            | 39:30                | 17           |
| Esmaili et.al      | 2006 | Iran     | 70     | P            | NA                   | 20           |
| Boskovic et.al     | 2014 | Serbia   | 109    | R            | NA                   | 16           |
| Rastogi et.al      | 2009 | India    | 49     | R            | 39:10                | 17           |
| Russo et.al        | 2016 | United States | 316  | R            | 159:157              | 16           |
| Tolia et.al        | 1986 | United States | 28   | U            | NA                   | 14           |
| Dehghani et.al     | 2006 | Iran     | 65     | P            | 34:31                | 16           |
| Movat et.al        | 1976 | UK       | 137    | P            | NA                   | 18           |
| Guelrud et.al      | 1991 | Venezuela | 57    | P            | 23:34                | 16           |
| Faweya et.al       | 1991 | Iran     | 70     | P            | NA                   | 17           |
| Jensen et.al       | 2012 | United States | 128  | R            | 53:75                | 19           |
| Yachha et.al       | 1996 | India    | 96     | P            | NA                   | 15           |
| Park et.al         | 1997 | S.Korea  | 73     | P            | NA                   | 18           |
| Poddar et.al       | 2009 | India    | 101    | P            | 19:82                | 21           |
| Cox et.al          | 1987 | United States | 33   | P            | 14:19                | 18           |
| Ferry et.al        | 1985 | United States | 143  | R            | 59:84                | 17           |
| Hays et.al         | 1967 | United States | 132  | R            | NA                   | 14           |
| Lai et.al          | 1994 | Taiwan   | 126    | P            | 78:48                | 16           |
| Manolaki et.al     | 1983 | UK       | 86     | U            | 39:47                | 15           |
| Wongsawasdi et.al  | 2008 | Thailand | 61     | P            | 34:27                | 16           |

Table 2: Risk of Bias assessed by QUADAS-2.

| Author            | Year | Country   | Risk of Bias | Applicability Concerns |
|-------------------|------|-----------|---------------|------------------------|
| Yang et.al        | 2009 | China     | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Esmaili et.al     | 2006 | Iran      | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Boskovic et.al    | 2014 | Serbia    | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Rastogi et.al     | 2009 | India     | High:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Russo et.al       | 2016 | United States | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Tolia et.al       | 1986 | United States | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Dehghani et.al    | 2006 | Iran      | Low:Low:High:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Movat et.al       | 1976 | UK        | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Guelrud et.al     | 1991 | Venezuela | Low:Low:High:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Faweya et.al      | 1991 | Iran      | Low:Unclear:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Jensen et.al      | 2012 | United States | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Yachha et.al      | 1996 | India     | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Park et.al        | 1997 | S.Korea   | Low:Low:Low:Low:Unclear:Low | Low:Low:Low:Low:Low:Low |
| Poddar et.al      | 2009 | India     | Low:Low:Low:Low:Low:Unclear | Low:Low:Low:Low:Low:Low |
| Cox et.al         | 1987 | United States | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Ferry et.al       | 1985 | United States | Low:High:Low:High:Low:Low | Low:Low:Low:Low:Low:Low |
| Hays et.al        | 1967 | United States | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Lai et.al         | 1994 | Taiwan    | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Manolaki et.al    | 1983 | UK        | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
| Wongsawasdi et.al | 2008 | Thailand  | Low:Low:Low:Low:Low:Low | Low:Low:Low:Low:Low:Low |
Study characteristics

The characteristics of the studies are available in Table 1. The 20 studies involved 1582 people. 11 studies were prospective, 7 were retrospective and 2 could not be clearly identified. 10 studies were over 60 cases, 10 were less than 60 cases. Studies were published between 1967 and 2016. Studies most commonly collected from the United States (6/20), studies, followed by Iran (3/20), India (3/20), UK (2/20), China (2/20), S.Korea (1/20), Thailand (1/20), Sebria (1/20), Venezuela (1/20). In 12 studies reporting gender 52.18% (n=1234) of participants were men. About the clear age of diagnosis is not mentioned. There are 7 articles [5,7-9,11,14,18] refer to the median age of operating liver biopsy, 4 articles refer to the jaundice index of patients [6,9,17,18], 2 articles about the needle of liver puncture [15,17]. Table 2 summarizes the quality assessment for the 20 full text studies. The overall quality of the included studies assessed by the QUADAS-2 was moderate, and all of the studies were of high quality that bias on 5 or more of the 7 items. In 20 articles, the authors make differentiation of BA from other cholangiologic jaundice such as infant hepatitis syndrome (IHS). There are main complications mentioned in 20 articles. The main complication is intraperitoneal hemorrhage. The second complication is pain around the puncture position. Others are not mentioned in 20 articles, but we found them in similar articles. In all studies conventional cholangiography was the reference standard.

Diagnostic values

Data on the diagnostic of liver biopsy were collected from 20 studies with 1582 patients. The Spearman correlation coefficient was -0.405, p value was 0.077, indicating no threshold effect. The diagnostic odds ratio was 170.39 (95% CI, 84.90-341.97), I² was 49.9%, showing medium heterogeneity among the studies (Figure 2).

![Figure 2: Diagnostic odds ratio of liver biopsy.](image-url)

The forest plot of the sensitivity and specificity of the diagnostic performance of liver biopsy is shown in Figure 3, 4. The sensitivities and specificities of individual studies varied from 50% to 100% and from 67% to 100%, respectively. The liver biopsy showed pooled sensitivity of 92% (95% CI, 90%–94%), specificity of 95% (95% CI, 93%–96%), LR+ and LR- are shown in Figure 5, 6. LR+ of 12.51 (95% CI, 8.04-19.46) and LR- of 0.09 (95% CI, 0.05-0.16). The summary ROC curves of liver biopsy for the diagnosis of BA are illustrated in Figure 7. The summary ROC curve was symmetric, and the AUC was 0.9761, Q was 0.9300. PPV was 93.84%, NPV was 92.84%. The accuracy was 93.30%.

Subgroup analyses

We compared the different median days of diagnosing BA in two groups, one is less than 60 day [7,9] another is more than 60 days [5,8,11,14,18]. We also compared the degree of jaundice. It can be stand for total bilirubin value and direct bilirubin value. It can be divided into two groups; one is the total bilirubin more than 3.0 mg/dL,direct bilirubin more than 40% total [6,17]. Another is the total bilirubin more than 2.0 mg/dL,direct bilirubin more than 20% total [9,18]. But one group is contained in another group, so analysis is meaningless. Only 2 articles mentioned with the needle, the size is both 18 mm [15,17], one said the length of puncture is 1 cm; another did not mentioned [17]. So the analysis of the size of needle is meaningless. The results are present in Table 3.

We also performed subgroup analyses and result was present in Table 4. In 20 articles, there are 10 articles using liver biopsy to differentiate BA from neonatal hepatitis, data also in Table 4. The heterogeneity evaluated liver biopsy is caused by study design and cases according to the results.
Figure 3: Sensitivity of liver biopsy.

Figure 4: Specificity of liver biopsy.
Figure 5: Positive likelihood ratio of liver biopsy.

Figure 6: Negative likelihood ratio of liver biopsy.
Publication bias

We constructed Desks funnel plot to assess publication bias of the studies liver biopsy (Supplemental Figure 8), the p value was 0.53, respectively. We can make a conclusion that this study had little publication bias.

Discussion

Data discussion

Sensitivity can evaluate the ability of finding true patients by liver biopsy. Specificity can react the ability of identifying people who don’t got disease. In this study, sensitivity is 92%, specificity is 95%, that means liver biopsy can make almost true diagnosis to true patient and can identify other disease from BA clearly. LR+ is the index of ratio of true positive to false positive. In this study, LR+ is 12.51, LR- is 0.09, it means that liver biopsy has little possibility to misdiagnose BA and wrong diagnosis. Accuracy can evaluate the ability of diagnosis patient and non-patient. The accuracy is 93.3%, can almost make a clear diagnosis that patient is or is not BA. PPV can predict morbidity if the diagnosis is positive. NPV can predict non-morbidity if the diagnosis is negative. In this study, PPV is 93.84%, NPV is 92.84%, that means if liver biopsy is positive, the patient has 93.84% possibility to have BA, if liver biopsy is negative, the patient has 92.84% possibility to have BA.

Table 3: Subgroup analyses of diagnosis day.

| Covariate           | Heterogeneity (I²) | Sensitivity (%) | Specificity (%) | DOR     | AUC    |
|---------------------|--------------------|-----------------|-----------------|---------|--------|
| Diagnosis Age       |                    |                 |                 |         |        |
| <60 days            | Yes (79.5%)        | 0.95            | 0.94            | 401.48  |        |
| >60 days            | No (45.1%)         | 0.95            | 0.97            | 355.49  |        |

Table 4: Subgroup analysis.

*Differential diagnosis from neonatal hepatitis means the articles use liver biopsy to differential diagnose BA from neonatal hepatitis.
Liver biopsy has high accuracy, specificity and sensitivity, PPV, NPV, AUC. The main use of liver biopsy is to know the degree of liver injury. And we can make a plan to treat. Also liver biopsy can make differentiation of BA from other cholestasis disease. In infant time, BA and infant hepatitis syndrome (IHS) are the common reason of obstructive jaundice. The liver tissue pathology of BA and IHS learn to change have many similarities such as: cholestasis, liver cell damage, hyperplasia of fibrous tissue, inflammatory cells infiltration, giant cells liver cells change, etc. There is still no unified standard of diagnosis and differential diagnosis. And other diseases such as concentrated bile plugs syndrome, biliary dysplasia, liver genetic metabolic disease and so on. BA required surgical treatment as soon as possible, while others are given priority to need medical treatment or liver transplantation [28].

Concentrated bile plugs syndrome, the liver biopsy showed mild change, no obvious fiber group woven and bile duct proliferation. Biliary dysplasia expressed intrahepatic bile ducts to reduce or disappear, but BA with hyperplasia.

Liver genetic metabolic disease is mainly to metabolism of sugar and fat disorder, such as glycogen storage disease with the common performance is liver disease change: swelling of liver cells and empty pale cytoplasm, nuclear small, thin like plant cell, PAS staining showed lots of positive substance in the liver cells. Some types can be a significant fibrosis, and for the development of cirrhosis of the liver. Bile duct lesions is not obvious, however, there will be no bile duct hyperplasia obviously.

General situation

Percutaneous liver biopsy was finished by Ehrlish in 1883 in Germany. In 1958, Nerghini reported liver biopsy in one second [25]. With the developing of technology, liver biopsy can be divided into the following categories: (1) The percutaneous blind puncture (Menghini method). (2) Ultrasound or CT guided liver biopsy; (3) Liver biopsy guided by laparoscopic. (4) Intraoperative liver biopsy. (5) Liver biopsy via vein [26]. Although liver biopsy has been carried out for a long time, but it is still difficult to popularize with a variety of reasons. In our opinion, liver biopsy has important value in determining the difficult liver disease, differentiate the pathological classification of viral hepatitis, making a direction on treatment and prognosis. It is one of most important research method with small side effects, safe in operation, and it cannot be replace by a lot of non-invasive detection method at present [27]. Although analysis shows high accuracy, specificity and sensitivity, PPV, NPV, AUC. But for infants, this is not only a trauma, but also a psychological pressure. And complications are inevitable.

Subgroup analysis

Diagnose days: data analyses show that the high accuracy occurred in 60 days (median).

The jaundice was diagnosed as BA occurred in total bilirubin more than 2.0 mg/dL, direct bilirubin more than 20% total.

The needle of puncture has no difference.
The shortcomings of liver biopsy

1. Liver biopsy is an invasive examination. There are many complications [29-31]. (1) The local biopsy site occurred pain and discomfort. (2) Mild transient hypotension (vascular vaguely reaction). (3) The right upper quadrant or right shoulder pain. (4) Intraperitoneal hemorrhage. (5) Bleeding of puncture site. It reported that 5.8%-13.5% infants appear transient bacteremia after liver biopsy. Bacteria in biliary obstruction or cholangitis occasionally develop into septicemia or shock. Mortality is about 1/10000-1/12000 [32]. (6) Other rare complications such as: biliary ascites, bile pleurisy, bile peritonitis, hemotherax, subcutaneous emphysema, pneumoperitoneum, scrotal emphysema, abscess under diaphragm.

There have been reported about 1-3% infants need hospitalization for complications, especially use the True-cut needle. Froehlich discovered that the incidence of complications lower in surgery doctors who did more than 50 cases per year [33].

2. The preoperative preparation and post-operation of liver biopsy are large work. Such as medicine and examination. Regular use vitamin K1 10 mg, vein input, once per day before 3 days to after 2 days of surgery [34]. Before liver biopsy, make some tests, platelets, etc [35].

3. Repeat sampling. Due to uneven of liver lesions, so need to repeated sample for the same liver and it can cause greater trauma [36].

4. The subjectivity of read tissue is strong. The literature said that infants with BA have the following features [37]: (1) The liver portal area occurred perilunate bilious liver fibrosis. (2) Portal area small bile duct hyperplasia, deformity, often associated with progressive developing fibrosis. (3) The formation of capillary bile duct silting bravery and interlobular bile duct bile plugs. (4) The hepatic portal vein and the surrounding inflammatory cells infiltration. (5) With few multinucleated giant liver cells.

5. The prognosis is related to the diagnosis time. Some patients need the second liver biopsy. Jolley reported that liver pathology in infants with significant changes occur in the growth of 3-4 weeks, due to cholestasis, the bile salts is not clear in time, mainly distribute around the portal vein. It caused that change. The change is significant in the portal area [38]. As a result, the different days of age influence the accuracy of diagnosis. Algale considered that combined the liver biopsy with other clinical manifestations can identify about 85% similar cases [39].

Comparison of advantage and shortcoming of liver biopsy

Although liver biopsy has many shortcomings, but the rate of complications is low, it can be avoided by developing of this technology. And it is necessary to make a pathological diagnostic criteria of BA. There are 4 articles [6-9,12] mentioned pathological diagnostic criteria which were different and this shortcoming should be solved. Although patients should do some pre-examinations, it is necessary for them to have these tests if BA is diagnosed and the surgery will be done in a few days. 10 articles using liver biopsy to differential diagnose BA from neonatal hepatitis, it has high sensitivity, specificity and AUC. So it’s a good way to distinguish BA from hepatitis. Other articles about BA and cholestasis, it’s also a good technology to distinguish BA from other cholestasis.

In a word, liver biopsy has shortcomings, but it is a good way to diagnose BA, and make differential diagnosis from cholestasis. The accuracy is high; we can use liver biopsy before cholangiography and surgery. It is noteworthy that doctors should improve technology, make a clear pathological diagnostic criteria and communicate to patients and relatives.

Limitations

Our study has several limitations. First: We do not have enough data to do the subgroup analyses. And in subgroup, the changing factor is not uniqueness, the results of subgroups show the heterogeneities, because the heterogeneities are caused by other aspects such as years, technology. Second, the articles screening has bias, this reason can do a lot of work on heterogeneities. Third, about the days of age, in 20 articles, there are not the actually data about days, only the mid age, it cannot on behalf of the patients’ conditions of disease. As we all know, BA is a disease with progressive and obstructive biliary, the prognosis is related to the diagnosis time. But the progress of liver pathology is different in patients with different days of age.

Conclusions

The results of Meta analyze is that liver biopsy is a important method in diagnosing BA. With high accuracy, it can be used in the clinic. But it has many short comings, so we need to avoid the appearance of complications and normalized use this technology.

Funding

This work was partially supported by Natural science foundation of xinjiang uygur autonomous region: The mechanism of Notch pathway in hepatic fibrosis of biliary atresia (2019D01A12). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests

Jianghua Zhan is currently receiving a grant (2019D01A12) from the Natural science foundation of xinjiang uygur autonomous region: The mechanism of Notch pathway in hepatic fibrosis of biliary atresia. For the remaining authors, none is declared.

References

1. Lee WS, Chai PF, Lim KS, Lim LH, Looi LM, et al. (2009) Outcome of BA in Malaysia: A single-centre study. J Paediatr Child Health 45: 279-285.
2. Yeh MM (2006) Pathologic diagnosis of BA on liver biopsy: is tissue the issue? J Gastroenterol Hepato 24: 936-8.
3. El-Guindi MA, Sira MM, Sira AM, Salem TA, El-Abd OL, et al. (2014) Design and validation of a diagnostic score for BA. J Hepatol 61: 116-123.
4. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, et al. (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155: 529.
5. Yang JG, Ma DQ, Peng Y, Song L, Li CL, et al. (2009) Comparison of different diagnostic methods for differentiating BA from idiopathic neonatal hepatitis. Clin Imaging 33: 439-446.
6. Esmaili J, Izadyar S, Kargari 1, Gholamrezahehad A (2007) BA in infants with prolonged cholestatic jaundice: diagnostic accuracy of hepatobiliary scintigraphy. Abdom Imaging 32: 243-247.
7. Boskovic A, Kitić I, Prokić D, Stankovic I, Grujić B, et al. (2014) Predictive value of hepatic ultrasound, liver biopsy, and duodenal tube test in the diagnosis of extrahepatic BA in Serbian infants. Turk J Gastroenterol 25: 170-174.
8. Rastogi A, Krishnani N, Yachha SK, Khanna V, Poddar U, et al. (2009) Histopathological features and accuracy for diagnosing BA by prelaparotomy liver biopsy in developing countries. J Gastroenterol Hepatol 24: 97-102.

9. Russo P, Magee JC, Anders RA, Bove KE, Chung C, et al. (2016) Key Histopathologic Features of Liver Biopsies That Distinguish BA From Other Causes of Infantile Cholestasis and Their Correlation With Outcome. Am J Surg Pathol 40: 1601-1605.

10. Tolia V, Dubois RS, Kagawalla A, Fleming S, Dua V, et al. (1986) Comparison of radionuclide scintigraphy and liver biopsy in the evaluation of neonatal cholestasis. J Pediatr Gastroenterol Nutr 5: 30-34.

11. Dehghani SM, Haghhighat M, Imamieh MH, Geramizadeh B, et al. (2006) Comparison of different diagnostic methods in infants with cholestasis. World J Gastroenterol 12: 5893.

12. Mowat AP, Psacharopoulos HT, Williams R (1976) Extrahepatic BA versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child 51: 763-770.

13. Guelrud M, Jaen D, Mendoza S (1991) ERCP in the diagnosis of extrahepatic BA. Gastrointest Endosc 37: 522-526.

14. Faweya AG, Akinrinola OO, Sodeinde O (1991) Duodenal intubation and aspiration test: utility in the differential diagnosis of infantile cholestasis. Gastrointest Endosc 13: 290-292.

15. Jensen MK, Blank VF, Moe DC, Simpson PM, Li SH, et al. (2012) HIDA, percutaneous transhepatic cholecysto-cholangiography and liver biopsy in infants with persistent jaundice: can a combination of PTCC and liver biopsy reduce unnecessary laparotomy? Pediatr Radiol 42: 32-39.

16. Yachha SK, Khanduri A, Kumar M, Sikora SS, Saxena R, et al. (1996) Neonatal cholestasis syndrome: an appraisal at a tertiary center. Indian Pediatr 33: 729-734.

17. Park WH, Choi SO, Lee HJ, Kim SP, Zeon SK, et al. (1997) A new diagnostic approach to BA with emphasis on the ultrasonographic triangular cord sign: comparison of ultrasonography, hepatobiliary scintigraphy, and liver needle biopsy in the evaluation of infantile cholestasis. J Pediatr Surg 32: 1555-1559.

18. Poddar U, Thapa BR, Das A, Bhattacharya A, Rao KL, et al. (2009) Neonatal cholestasis: differentiation of BA from neonatal hepatitis in a developing country. Acta Paediatr 98: 1260-1264.

19. Cox KL, Stadnik RC, Mcghan JP, Sanders K, Cannon RA, et al. (1987) Hepatobiliary scintigraphy with technetium-99m disofenin in the evaluation of neonatal cholestasis. J Pediatr Gastroenterol Nutr 6: 885-891.

20. Ferry GD, Selby ML, Udlall J, Finegold M, Nichols B, et al. (1985) Guide to early diagnosis of biliary obstruction in infancy: review of 143 cases. Clin Pediatr 24: 305-11.

21. Hays DM, Woolley MM, Snyder WH Jr, Reed GB GWNN JL, Linding BH, et al. (1967) Diagnosis of BA: relative accuracy of percutaneous liver biopsy, open liver biopsy, and operative cholangiography. J Pediatr 71: 598-607.

22. Lai MW, Chang MH, Hsu SC, Hsu HC, Su CT, et al. (1994) Differential diagnosis of extrahepatic BA from neonatal hepatitis: a prospective study. J Pediatr Gastroenterol Nutr 18: 121-127.

23. Manolaki AG, Larcher VF, Mowat AP, Barrett JJ, Portmann B, et al. (1983) The prelaparotomy diagnosis of extrahepatic BA. Arch Dis Child 58: 591-594.

24. Wongsawadi L, Ukarapol N, Visrutaratna P, Singhavejsakul J, Kattipattanapong V, et al. (2008) Diagnostic evaluation of infantile cholestasis. J Med Assoc Thai 91: 345-349.

25. Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344: 495-500.

26. Yang JG, Ma DQ, Peng Y, Song L, Li CL, et al. (2009) Comparison of different diagnostic methods for differentiating BA from idiopathic neonatal hepatitis. Clin Imaging 33: 439-446.

27. Javad E, Sina L, Iraj K, Ali G (2007) BA in infants with prolonged cholestatic jaundice: diagnostic accuracy of hepatobiliary scintigraphy. Abdom Imaging 32: 243-247.

28. Zhou K, Wang J, Xie G, Zhou Y, Yan W, et al. (2015) Distinct Plasma Bile Acid Profiles of BA and Neonatal Hepatitis Syndrome. J Proteome Res 14: 4844-4850.

29. Boskovich A, Katic I, Prokic D, Stankovic I, Grujic B, et al. (2014) Predictive value of hepatic ultrasound, liver biopsy, and duodenal tube test in the diagnosis of extrahepatic BA in Serbian infants. Turk J Gastroenterol 25: 170-174.

Citation: Yang Y, Li X, Zhan J (2020) The Accuracy of Liver Biopsy to Diagnose Biliary Atresia: A Meta-Analysis. Int J Clin Res Trials 5: 144. doi: https://doi.org/10.15344/2456-8007/2020/144